Other adverse events were similar in both groups, except that inhaled human insulin was associated with a higher incidence of mild cough and dyspnea.

The most common presenting symptoms were dyspnea, cough and fatigue.

Failure of the lung to disperse inevitably leads to dyspnea, chest oppression, cough and panting.